Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop
... in October 2008 for routine prophylaxis against hereditary angioedema (HAE) attacks in adults and ... page 27: Prophylactic Therapy Considerations in hereditary Angioedema In an abstract ... Should Prophylactic Therapy be Considered for hereditary Angioedema?', Dr. Tim Craig, et al. described ...ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
... successfully treated all types of acute hereditary angioedema (HAE) attacks seen in the study ... entitled "Shortcomings in the diagnosis of hereditary angioedema: Are we adequately screening family ... a challenge, and despite the fact that HAE is a hereditary disorder, testing family members is not common ...ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
... Exclusivity for Prophylaxis against hereditary Angioedema - EXTON, Pa., Oct. 21 ... attacks in adolescent and adult patients with hereditary angioedema (HAE). hereditary angioedema, or C1 esterase inhibitor (C1-INH) ...Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies
... for Healthcare Professionals VOORHEES, N.J., March 17 /PRNewswire/ -- hereditary angioedema (HAE) is estimated to afflict 10,000 people in the United ... States. This continuing education activity, titled Changing Paradigms in hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies, is supported ...Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
... company, Jerini AG for an equity purchase price of EUR328 million adding hereditary angioedema (HAE) product, FIRAZYR(R), to its Human Genetic Therapies ... stability. FIRAZYR will be packaged in a pre-filled syringe. About hereditary Angioedema (HAE) HAE is a debilitating and potentially life-threatening ...Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
... open-label phase 2 study is designed to enroll up to 34 patients with hereditary or sporadic papillary renal cell carcinoma. Eligible patients are ... potent activity against mutationally activated forms of MET found in hereditary papillary renal cell carcinomas. The compound also demonstrated ...Genetic Source of Rare Childhood Cancer Found; Gene is Implicated in Other Cancers
... those of normal tissue, which pointed toward a possible role for DICER1 in cancer," says senior author Paul Goodfellow, Ph.D., co-director of the hereditary Cancer Core at the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis. "Very recently, other ...ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
... strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package ...ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
... strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package ...ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer
... 30 percent are thought to result from cigarette smoking. Some other risk factors scientists are currently studying include: diabetes, chronic and hereditary pancreatitis (inflammation of the pancreas), obesity, physical activity, and diet. "Screening for pancreatic cancer in relatives of affected ...Young Women Diagnosed with Early-Stage Breast Cancer More Likely to Die than Older Women
... to genetics. Indeed, about 20 percent of young women diagnosed with breast cancer have a significant family history of the disease. Unfortunately, hereditary breast cancers tend to have a poorer outcome than nonhereditary types. Dr. Margenthaler is hopeful that this research will increase the awareness ...Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children
... information is key for parents to feel comfortable, adds one parent, whose daughter is participating in a study on a treatment for Marfan syndrome, a hereditary condition that weakens connective tissue, often leading to dangerous problems in the heart and blood vessels, as well as bones and joints, eyes, and ...Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
... Lukacs will contribute to the intellectual capital of Axentis Pharma." About cystic fibrosis Cystic fibrosis is the most common life-threatening hereditary disease amongst Caucasian populations. The disease is caused by a mutation in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene ...Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
... developmental disorders caused by mutation of the ARX gene, Duchene's muscular dystrophy, myotonic dystrophy (DM1), Freidreich's Ataxia (FRDA), hereditary neuropathy with pressure palsies, polycystic kidney disease, spinal muscular atrophy (SMN1), spinocerebellar ataxia (SCA1, 2, 3, 6, 7 and 8) and ...Gene Therapy Improves Vision in Patients with Congenital Retinal Disease
... for the ongoing research for the past 14 years. The F.M. Kirby Center was the first molecular biology center devoted to developing gene therapy for hereditary causes of vision loss. The Center serves as home to the laboratories of seven investigators who conduct research on the cellular and molecular ...Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease
... (AAT), suggesting the need for broader criteria for AAT deficiency testing. AAT deficiency, also known as Alpha-1, is a widely undiagnosed hereditary disorder that is usually fatal in its severe form. Alpha-1 is estimated to affect up to 100,000 Americans, but up to 95 percent are undiagnosed or ...GlaxoSmithKline Accelerates Review of Exelixis' XL880
... studies, XL880 inhibited its targets with nanomolar potency, and retained potent activity against mutationally activated forms of MET found in hereditary papillary renal cell carcinomas. The compound also demonstrated dose-dependent tumor growth inhibition in models of breast cancer, colorectal cancer, ...Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
... inhibitor (C1-INH) for the acute treatment of hereditary angioedema (HAE). In the acute study, which is part of the company's CHANGE trials (C1-inhibitor in hereditary Angioedema Nanofiltration Generation evaluating ... company's Chief Executive Officer. About hereditary Angioedema HAE, ...DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)
... trial, EDEMA3, for its lead product candidate DX-88 (ecallantide), for hereditary angioedema (HAE). A webcast presentation of the EDEMA3 data is scheduled ... three Phase 2 trials and a Phase 3 trial of DX-88 for the treatment of hereditary angioedema (HAE). A confirmatory study, known as EDEMA4, is planned and ...Cogane Data Presented at ‘11th International Congress of Parkinson’s Disease and Disorders’
... The cause of Parkinson's disease in the majority of cases is unknown (idiopathic Parkinson's disease), though some cases have been found to have a hereditary component (familial Parkinson's disease) and possible mechanisms include oxidative damage of nerve cells coupled with loss of neurotrophic factors. ...Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
... clot buster and offers a natural alternative to synthesized solutions to address an unmet need of the market. A1PI is used by patients suffering from hereditary emphysema resulting from A1PI deficiency. A1PI deficiency affects between 60,000 to 100,000 people in the United States. According to Cowen and ...